My research focused on the role of intratumoral T cell heterogeneity for response to immune checkpoint blockade in human lung cancer.
In 2016, I joined the lab of Prof. Ton Schumacher at the Netherlands Cancer Institute with a postdoctoral fellowship from the Swiss National Science Foundation. Here, I continued my work on understanding the heterogeneity in intratumoral immune activity and developed human tumor explant models to study patient-specific immunotherapy responses ex vivo. In 2019, I received the Swiss Pfizer Research Prize in Oncology for my work on the role of distinct dysfunctional T cell subsets on immunotherapy response in human lung cancer.